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Background: Obesity is associated with impaired vascular function. In the
cardiovascular system, protease-activated receptor 2 (PAR2) exerts multiple functions
such as the control of the vascular tone. In pathological conditions, PAR2 is related to
vascular inflammation. However, little is known about the impact of obesity on PAR2 in
the vasculature. Therefore, we explored the role of PAR2 as a potential link between
obesity and cardiovascular diseases.
Methods: C57BL/6 mice were fed with either a chow or a 60% high fat diet for
24 weeks prior to isolation of aortas. Furthermore, human coronary artery endothelial
cells (HCAEC) and human coronary smooth muscle cells (HCSMC) were treated with
conditioned medium obtained from in vitro differentiated primary human adipocytes. To
investigate receptor interaction vascular endothelial growth factor receptor 2 (VEGFR2)
was blocked by exposure to calcium dobesilate and a VEGFR2 neutralization antibody,
before treatment with PAR2 activating peptide. Student’s t-test or one-way were used to
determine statistical significance.
Results: Both, high fat diet and exposure to conditioned medium increased PAR2
expression in aortas and human vascular cells, respectively. In HCSMC, conditioned
medium elicited proliferation as well as cyclooxygenase 2 induction, which was
suppressed by the PAR2 antagonist GB83. Specific activation of PAR2 by the PAR2
activating peptide induced proliferation and cyclooxygenase 2 expression which were
abolished by blocking the VEGFR2. Additionally, treatment of HCSMC with the PAR2
activating peptide triggered VEGFR2 phosphorylation.
Conclusion: Under obesogenic conditions, where circulating levels of pro-inflammatory
adipokines are elevated, PAR2 arises as an important player linking obesity-related
adipose tissue inflammation to atherogenesis. We show for the first time that
the underlying mechanisms of these pro-atherogenic effects involve a potential
transactivation of the VEGFR2 by PAR2.
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GRAPHICAL ABSTRACT | Upregulation and activation of PAR2 by elevated levels of pro-inflammatory cytokines, lead to pro- atherogenic events, such
as smooth muscle cell proliferation, COX2 and NFkB induction.
INTRODUCTION
Obesity is associated with comorbidities such as type 2 diabetes
and cardiovascular diseases (CVD) (Despres, 2012). CVD are
the main cause for deaths in diabetes mellitus (Morrish et al.,
2001) and lead to a significant increase in obesity-associated
mortality (Lloyd-Jones et al., 2010). The development of obesity
is a consequence of imbalance between energy intake and energy
expenditure causing storage of excessive energy in the adipose
tissue (AT) (Hill et al., 2012). Besides being a storage organ, it
is well established that AT influences systemic metabolism as
an endocrine organ secreting a variety of proteins referred to as
adipokines (Trayhurn et al., 2011). During the progress of obesity
AT undergoes modulation such as the enlargement of adipocytes,
Abbreviations: AT, Adipose tissue; BMI, Body mass index; CM, Conditioned
media; COX2, Cyclooxygenase 2; CVD, Cardiovascular disease; FCS, Fetal calf
serum; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; HCAEC, Human
coronary artery endothelial cells; HCSMC, Human coronary smooth muscle cells;
HFD, High fat diet; PAR2, Protease-activated receptor 2; PAR2-AP, Protease-
activated receptor 2 activating peptide; SEM, Standard error of the mean;
VEGF, Vascular endothelial growth factor; VEGFR2, Vascular endothelial growth
factor receptor 2; VEGFR2-NA, Vascular endothelial growth factor receptor 2
neutralizing antibody.
or a switch in the secretome toward a prominent release of
pro-inflammatory adipokines (Ouchi et al., 2011). In turn,
these adipokines are known as inflammatory factors promoting
insulin resistance (Hotamisligil et al., 1995). Furthermore, it has
been proposed that high levels of circulating pro-inflammatory
adipokines found in diseases such as obesity and type 2 diabetes
mellitus have an impact on cardiovascular function (Greenberg
and Obin, 2006). Thus, adipokines represent a molecular link
between metabolic and cardiovascular diseases (Taube et al.,
2012). There is evidence that they can directly exert deleterious
effects on both endothelial and smooth muscle cells resulting
in damage of the vasculature (Karastergiou and Mohamed-Ali,
2010; Lamers et al., 2011; Schlich et al., 2013).
In 1994, protease-activated receptor 2 (PAR2), a seven
transmembrane domain, G-protein-coupled receptor, was
discovered by Nystedt et al. (1994) and has been found to be
expressed in endothelial (Mirza et al., 1996) as well as in smooth
muscle cells (Molino et al., 1998). While PAR1, PAR3, and PAR4
activation is driven by thrombin, PAR2 is activated by serine
proteases such as tryptase, factor Xa, trypsin and the TF-FVIIa
complex (Adams et al., 2011). The proteolytic cleavage of the
extracellular N-terminal domain leads to the unmasking of a
tethered ligand which then binds to a binding pocket in the
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receptor (Dery et al., 1998). In addition, PAR2 activation can be
triggered by synthetic peptides mimicking the sequence of the
tethered ligand (Macfarlane et al., 2001). In the vascular wall,
activation of PAR2 initiates multiple signaling pathways exerting
distinct responses, among others the control of vascular tone,
and coagulation (Sriwai et al., 2013; Zhao et al., 2014).
Under pathological conditions, PAR2 is involved in
cardiovascular responses such as vasorelaxation and
vasoconstriction, as well as inflammatory processes (Hirano
and Kanaide, 2003; Aman et al., 2010; Adams et al., 2011). For
instance, administration of PAR2 agonists such as SLIGKV or
trypsin induce proliferation in smooth muscle (Bono et al.,
1997) and endothelial cells (Mirza et al., 1996). Moreover,
smooth muscle cell proliferation via PAR2 can be triggered
by pro-inflammatory adipokines such as DPP4 (Wronkowitz
et al., 2014). In vivo, PAR2 activation drives the development of
hypertension (Emilsson et al., 1997; Cicala et al., 1999) and PAR2
expression is enhanced in aortas of diabetic mice and in human
coronary atherosclerotic lesions (McGuire, 2004; Napoli et al.,
2004). Furthermore, upregulation of PAR2 content also occurs
in endothelial cells and coronary arteries after treatment with
inflammatory stimuli such as interleukin (IL)-1α, IL-1β, and
tumor necrosis factor (TNF)-α (Nystedt et al., 1996; Hamilton
et al., 2001; Ritchie et al., 2007). Overall, these studies suggest
that PAR2 is an important player in both endothelial and
smooth muscle cell function as well as in the overall control of
vascular reactivity. However, the role of PAR2 in obesity-related
vascular diseases remains unclear. Therefore, we addressed
the importance of PAR2 in the vasculature under obesogenic
conditions.
MATERIALS AND METHODS
Animal Model
Animal care and use were approved by the local Animal Ethics
Committee according to the principles outlined in the European
Commission Council Directive (86/609/EEC). C57BL/6J mice
were obtained from Jackson laboratories. Twelve week old mice
were either fed a high fat diet (HFD, 60% kcal fat; Research
diets D12492) or standard chow diet over 24 weeks. Animals
were housed in polyacrylamide cages under temperature control
(22◦C) and a 12 h light/dark cycle. Mice were weighted every
4 weeks. After 24 weeks on the respective diets mice were
sacrificed by cervical dislocation. Aortas were collected, cleaned
of fat, snap frozen in liquid nitrogen and stored at −80◦C until
further analysis.
Preparation of Explants
Visceral AT from chow and HFD animals were collected in
cold PBS supplemented with an antibiotic-antimycotic solution
(Invitrogen, Carlsbad, CA, USA). Connective tissue and vessels
were removed and fat pads were cut into small pieces. After
washing three times in PBS, liquid was removed by putting
explants on a sterile mesh. Relatively dry fat pieces were
weighted and 100mg of AT were incubated in 1 ml of HCSMC
starvation medium (fetal calf serum (FCS)-free DMEM low
glucose (Invitrogen, Carlsbad, CA, USA) at 37◦C and 5%CO2 to
generate conditionedmedium (CM). After 24 h CMwas collected
and centrifuged at 1200 rpm for 10min and stored at−20◦C until
further use.
Isolation of Preadipocytes and Generation
of Human Adipocyte CM
Preadipocytes were isolated from human abdominal AT obtained
frommoderately overweight or obese subjects undergoing plastic
surgery following the protocol previously described and being
approved by the ethical committee of the Heinrich-Heine-
University (Düsseldorf, Germany; Hauner et al., 1995).
Preadipocytes were cultured in DMEM/F12 medium (Gibco
Invitrogen, Carlsbad, CA, USA) supplemented with 33 µmol/l
biotin (Sigma-Aldrich, Schnelldorf, Germany), 17 µmol/l d-
panthothenic-acid (Sigma-Aldrich, Schnelldorf, Germany), 14
nmol/l NaHCO3 (Merck, Darmstadt, Germany), human insulin
(100 nM, Sigma-Aldrich, Schnelldorf, Germany), dexamethasone
(1 µM, Sigma-Aldrich, Schnelldorf, Germany), and 10% FCS
(Gibco Invitrogen, Carlsbad, CA, USA) and grown until 90%
confluence. Then differentiation was induced by addition of
0.25 µM troglitazone (Sigma-Aldrich, Munich, Germany) and
0.2 mM IBMX (Sigma-Aldrich, Munich, Germany). The switch
to differentiation medium is indicated as day 0. After 7 days,
medium was changed to maintenance medium (differentiation
medium deprived of troglitazone and IBMX) until day 14.
Medium was changed every 2–3 days. On day 14, cells were
treated with either human coronary artery endothelial cell
(HCAEC) starvation medium composed of endothelial cell basal
medium MV and 5% FCS or HCSMC starvation medium
(DMEM low glucose, 0% FCS) for 48 h. CM was collected,
centrifuged at 1200 rpm for 10 min and stored at −20◦C until
further use.
Cell Culture
HCAEC obtained from three different donors were purchased
from PromoCell (Heidelberg, Germany) and cultured in
endothelial cell basal medium MV (PromoCell, Heidelberg,
Germany) supplemented with 20% FCS, 1µg/ml hydrocortisone,
0.004 ml/ml ECGS and 10 ng/ml EGF at 37◦ C and 5% CO2.
Cells between passages 4–7 were used for experiments. When
90% confluence was reached HCAEC were washed with PBS
and treated with CM. HCSMC from four different donors were
purchased from PromoCell (Heidelberg, Germany), tebu-bio
(Offenbach, Germany), and Lonza (Basel, Switzerland) were
seeded in HCSMC growth medium (DMEM low glucose,
Invitrogen, Carlsbad, CA, USA) containing 10% FCS and
cultivated according to manufacturer’s protocol at 37◦ C and
5% CO2. After reaching 90% confluence, cells were washed with
PBS and serum starved for 24 h. HCSMC were then treated
with CM or PAR2 activating peptide (PAR2-AP, SLIGKV-NH2;
50 µM, Bachem, Bubendorf, Switzerland). All experiments were
performed in cells at passage 3.
Immunoblotting
Cells were lysed in a lysis buffer composed of 50 mM HEPES
(Promocell, Heidelberg, Germany), 1% TritonX100 (Sigma-
Aldrich, Munich, Germany), complete protease inhibitor and
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PhosStop phosphatase inhibitor cocktail at pH 7.4 (Roche, Basel
Switzerland). Protein lysates were diluted with Laemmli buffer
and denatured for 5 min at 94◦C. Five microgram protein were
loaded on a 10% gel SDS-PAGE and transferred to a PVDF
membrane during blotting process. Reagents for SDS-PAGE
were supplied by Amersham Pharmacia Biotech (Braunschweig,
Germany) and by Sigma-Aldrich (Munich, Germany). Blots were
blocked in a Tris-buffered saline solution containing 0.1% Tween
and 5% milk powder and incubated with antibodies against:
PAR2 (SAM11: sc-13504, Santa Cruz Biotechnology, Heidelberg,
Germany), COX2 (#4842), GAPDH (#2118), phospho-VEGFR2
(Tyr1059) (#3817), VEGFR2 (#2479), NF-κB p65 (#8242), and
phospho-NF-κB p65 (Ser536) (#3033). Unless otherwise stated,
all antibodies were purchased from Cell signaling Technology
(Frankfurt, Germany). We used the corresponding secondary
HRP-coupled antibodies against mouse and rabbit (Promega,
Mannheim, Germany). After washing, blots were exposed to
Immobilon HRP substrate (Millipore, Billerica, MA, USA) and
analyzed with a VersaDoc 4000 MP work station (BIO-RAD,
Munich, Germany).
qRT-PCR
RNA isolation of human cells was performed in RLT lysis buffer
working solution containing 1% β-mercaptoethanol according
to manufacturer’s protocols. Murine aortas were lysed in 1
ml Tripure (Roche, Mannheim, Germany) by a tissuelyser II
(Qiagen, Hilden, Germany) for 5 min at 29 s−1 for mRNA
isolation. mRNA purification of cells and aortas was done with
an RNeasy Kit (Qiagen, Hilden, Germany) and content of
mRNA was measured with a NanoDrop2000 (Thermo Scientific,
Schwerte, Germany). All samples were reversely transcribed into
1 µg/µl of cDNA using an Omniscript RT Kit (Qiagen, Venlo,
Netherlands) and mRNA levels were determined by StepOne
Plus real-time PCR system (Applied Biosystems, Carlsbad,
CA, USA). Primers from Qiagen were used: Hs_F2RL1_1_SG
(QT02589377), Hs_ACTB_2_SG (QT01680476) Hs_PTGS2_SG
(QF00461055), mM_F2RL1 (QT02255330), and Mm_Rn18S
(QT02448075).
Proliferation Assay
Prior to determination of proliferation, HCSMC were starved
for 24 h. Cells were pre-incubated with the specific PAR2
antagonist GB83 (10 µM, Axon Medchem, dissolved in DMSO),
the vascular endothelial growth factor receptor 2 neutralization
antibody (VEGFR2-NA, R&D Systems Wiesbaden-Nordenstadt,
Germany, MAB3572) or calcium dobesilate (Sigma-Aldrich,
Schnelldorf, Germany) for 1 h. Subsequently, cells were treated
either with CM alone, CM in combination with GB83, the PAR2
activating peptide (PAR2-AP, SLIGKV-NH2; 50 µM, Bachem,
Bubendorf, Switzerland), or PAR-AP in combination with the
VEGFR2-NA or dobesilate for 24 h. Five percentage FCS was
used as a positive control. All treatments contained 10% BrdU.
Proliferation was assessed by measuring BrdU incorporation
(Proliferation Assay, Roche, Mannheim, Germany) with a
microplate reader (Infinite M200, Tecan GmbH, Männersdorf,
Switzerland).
Caspase 3/7 Activity Assay
HCAEC were seeded in a 96-well plate and cultured for 24 h.
Cells were pre-treated with GB83 for 1 h and treated with CM
alone or in combination with GB83 (10 µM) for 18 h. H2O2
(200 µM, Sigma-Aldrich, Schnelldorf, Germany) was used as a
positive control. Caspase 3/7 activity was measured by a Caspase-
Glo R© 3/7 Assay (Promega, Mannheim, Germany) as described
in the manufacturer’s protocol. Luminescence was measured in a
microplate reader.
VEGF Release
In order to monitor vascular endothelial growth factor (VEGF)
release from HCSMC, supernatants were collected, centrifuged,
and stored at −80◦C. Supernatants were analyzed with a
VEGF ELISA Kit purchased from R&D Systems (Wiesbaden-
Nordenstadt, Germany).
Adipokine Array
The secretion profile of murine adipose explants was analyzed
by usage of a proteome profiler (R&D Systems, Wiesbaden-
Nordenstadt, Germany) according to manufacturer’s protocol.
Membranes were incubated with murine CM from chow and
HFD-fed animals.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism
software (La Jolla, CA, USA). Unpaired two-tailed Student’s t-
test or one-way ANOVA (post hoc test: Bonferroni or Dunnett’s)
were used to determine statistical significance considering a p-
value below 0.05 as statistically significant. Data are expressed as
mean values± SEM.
RESULTS
PAR2 Expression Is Elevated by HFD in
Murine Aortas and by Human
Adipocyte-Derived Factors in HCAEC and
HCSMC
Animals under HFD gained more weight compared to animals
given a chow diet (Figure 1A). To monitor the impact of obesity
on PAR2 expression in the vasculature of these mice, we analyzed
PAR2 levels in aortas carefully controlled to be free of adipose
tissue. PAR2 mRNA expression in aortas from HFD-fed animals
was significantly higher (11Ct of 1.2 ± 0.1) than in chow diet-
fed animals (11Ct of 0.8± 0.1) (Figure 1B). Furthermore, PAR2
expression was positively correlated with the body weight of
corresponding animals (Figure 1C). To determine whether the
observed changes in aortic PAR2 expression were specifically
related to AT, we analyzed the effect of CM from murine adipose
tissue explants on HCSMC. Exposure of HCSMC to CM of
animals under chow diet had no effect on PAR2 content while
treatment with CM obtained from HFD-fed animals provoked a
2-fold increase (Figure 1D).
Certain cytokines, which are elevated in obesity such as TNF-α
or IL-1α are able to induce PAR2 (Nystedt et al., 1996; Hamilton
et al., 2001). In order to explore the impact of adipokines on PAR2
induction, we generated CM from differentiated primary human
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FIGURE 1 | HFD induces PAR2 expression in the vascular wall. (A)
Weight gain in C57BL/6J wild type mice under HFD or chow diet for 24 weeks;
n = 11–27. (B) PAR2 mRNA expression in murine aortas after 24 weeks.
PAR2 expression was normalized to 18S mRNA levels; n = 7. (C) Correlation
of PAR2 mRNA expression in murine aortas and weight of respective animals;
n = 13. (D) CM from murine epidydimal AT of chow- and HFD-fed mice were
used to determine induction of PAR2 mRNA in HCSMC. Data are normalized
to ß-actin mRNA levels (*p < 0.05 vs. chow); n = 7. All data represent mean
values ± SEM (*p < 0.05). Conditioned medium (CM), High fat diet (HFD).
adipocytes obtained from overweight or obese subjects (BMI 30.1
± 1.9 kg/m2). Human vascular cells were exposed to adipocyte
CM. In HCSMC, PAR2 mRNA was significantly elevated up to
1.5 ± 0.2 fold over control after 1 h CM treatment (Figure 2A).
At protein level an increase in PAR2 expression occurred after 6
and 24 h (1.7 ± 0.2 fold over control, respectively; Figure 2B).
Moreover, PAR2 expression was enhanced in HCSMC exposed
to CM of obese subjects. While CM of subjects with a BMI
of 25 kg/m2 was only capable to induce PAR2 1.2 ± 0.2 fold
compared to non-treated cells, CM of subjects showing a BMI
of 37 kg/m2 could induce PAR2 to a significantly higher extent
(Figure 2C).
PAR2 Mediates CM-Induced Proliferation
in HCSMC
A change in intima-media thickness is an important event in
the development of vascular remodeling. (Langille, 1993) During
this process proliferation of smooth muscle cells results in
a thickening of the tunica media (Langille, 1993). Therefore,
using CM from human adipocytes we assessed proliferation in
HCSMC. Treatment of HCSMC with CM increased proliferation
3.3 ± 0.6 fold over control. Interestingly, we observed that this
effect was PAR2-dependent, since it was reduced by 70% with the
PAR2 specific antagonist GB83 (Figure 3A).We further observed
a trend toward higher mitogenic activity due to stronger PAR2
expression in HCSMC (Figure 3B, p = 0.06). PAR2 involvement
during HCSMC proliferation was supported by the initiation of
proliferation with PAR2-AP (Figure 3C).
CM Induced PAR2 Levels and Apoptosis in
HCAEC
In HCAEC, CM treatment resulted in a biphasic increase of
PAR2 expression at mRNA level (Supplementary Figure 1A),
whereas PAR2 was gradually enhanced at protein level with a
peak of 2.1 ± 0.4 fold over control after 24 h (Supplementary
Figure 1B). Since the proliferation of smooth muscle cells during
vascular remodeling is accompanied by endothelial cell apoptosis
(Langille, 1993), we investigated the impact of adipocyte CM
on caspase3/7 activity in HCAEC. Apoptosis of HCAEC was
increased by CM and effects of CM were prevented by the PAR2
antagonist GB83 (Supplementary Figure 1C). GB83 alone had no
effect on either cell proliferation or apoptosis.
Induction of Cyclooxygenase 2 Levels
Occurs Via PAR2
Since cyclooxygenase 2 (COX2) is a key mediator of
inflammation and vascular dysfunction (Vane and Botting,
1998; Bagi et al., 2006), we investigated the potential regulation
of COX2 by CM. We exposed HCSMC cells to CM for the
indicated time points. CM treatment triggered an enhancement
of COX2 expression at mRNA level with a peak at 1 h (2.4
± 0.4 fold over control; Figure 4A) and a peak at protein
levels at 24 h (2 ± 0.3 fold over control; Figure 4B). One hour
pre-incubation of HCSMC with the specific PAR2 antagonist
GB83 downregulated CM-induced COX2 expression to basal
levels (Figure 4C). Additionally, we detected a rise in COX2
protein level after challenging cells with the PAR2-AP for 1 h
(1.5± 0.2 fold over control) and 2 h (1.6± 0.1 fold over control;
Figure 4D). As a marker of pro-inflammatory signaling, we
examined phosphorylation of the transcription factor NF-κB.
After 24 h CM-induced phosphorylation of NF-κBwas prevented
by GB83 (Figure 4E). Accordingly, phosphorylation of NF-κB in
HCSMCwas induced by the PAR2 agonist PAR2-AP (Figure 4F).
PAR2 Activation Leads to Proliferation and
COX2 Induction in a VEGFR2
Dependent-Manner
As previously described by Schlich et al., VEGF which signals
through the vascular endothelial growth factor receptor 2
(VEGFR2) (Ferrara et al., 2003), is a main contributor to
smooth muscle cell proliferation (Schlich et al., 2013). Here,
we found increased VEGF levels in CM of adipose explants
from mice upon HFD (Supplementary Figure 2A). In addition,
VEGF release from human adipocytes correlated with BMI
of adipose tissue explant donors (Supplementary Figure 2B).
In order to explore if the VEGFR2 was involved in PAR2-
mediated proliferation and COX2 induction, we blocked the
VEGFR2 by usage of dobesilate and VEGFR2-NA. Indeed, pre-
incubation with either the inhibitor dobesilate or a VEGFR2-NA
for 1 h and subsequent treatment with PAR2-AP resulted in a
reduction of proliferation back to basal levels (1.0 ± 0.1 fold
and to 0.9 ± 0.1 fold compared to control levels, respectively).
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FIGURE 2 | PAR2 induction by adipocyte-derived factors in HCSMC. (A,B) Time course of PAR2 mRNA and protein expression after CM treatment for indicated
time points was assessed by qRT-PCR and western blot in HCSMC. Data were normalized to β-actin or GAPDH levels respectively; n = 4–6 (*p < 0.05 vs. time 0).
(C) PAR2 expression in HCSMC after challenge to CM for 1 h and its relation to BMI of AT donors, n = 15 (*p < 0.05). Data represent mean values ± SEM.
Conditioned medium (CM), human coronary smooth muscle cells (HCSMC).
FIGURE 3 | PAR2 mediated proliferation in HCSMC. (A) Proliferation was assessed by BrdU incorporation after 1 h pre-incubation with GB83 (10 µM) and
subsequent treatment with either CM alone or in combination with GB83 for 24 h in HCSMC. FCS (5%) was included as a positive control. (B) Correlation of PAR2
induction after 24 h and proliferation rate by CM; n = 8. (C) Effects of PAR2-AP (50 µM) on proliferation was analyzed after 24 h; n = 4–6. Data represent mean values
± SEM (*p < 0.05 vs. control). Conditioned medium (CM), fetal calf serum (FCS), human coronary smooth muscle cells (HCSMC), PAR2-activating peptide (PAR2-AP).
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FIGURE 4 | CM induces COX2 expression in HCSMC via PAR2. COX2 expression was determined in HCSMC exposed to CM for the indicated time points and
(A) mRNA and (B) protein levels were quantified. n = 4–6. (C) CM-induced COX2 expression after 24 h and pre-incubation with PAR2 antagonist GB83 (10 µM); n =
6. (D) Time course of COX2 induction by PAR2-AP (50 µM); n = 6. (E) CM-induced pNF-κB expression after 24 h and pre-incubation with PAR2 antagonist GB83,
n = 4. (F) Time course of pNF-κB expression by PAR2-AP, n = 5. Data of mRNA target gene levels are normalized to β-actin. Protein expression of COX was
normalized to GAPDH and pNF-κB was normalized to tNF-κB. Data are mean values ± SEM (*p < 0.05 vs. time 0 or control). Conditioned medium (CM), human
coronary smooth muscle cells (HCSMC), PAR2-activating peptide (PAR2-AP).
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VEGFR2 blockade alone had no effect on HCSMC proliferation
(Figure 5A). Furthermore, PAR2-AP-mediated COX2 induction
of 1.5 ± 0.1 fold over control was diminished to 1.1 ± 0.03
fold over control after VEGFR2-NA and to 1.1 ± 0.1 fold over
control after dobesilate addition (Figure 5B). Next, we explored
if PAR2 activation affected VEGFR2 phosphorylation. After 2 h
we observed an enhanced receptor phosphorylation (Figure 5C),
while total VEGFR2 content was unaltered (Data not shown).
However, VEGFR2 activation did not occur due to increased
VEGF levels since exposure of HCSMC to PAR2-AP did not alter
VEGF release compared to control conditions (Figure 5D).
DISCUSSION
The development of obesity is associated with functional
and structural changes in the AT (Ouchi et al., 2011).
Particularly, during obesity, AT switches to a more pro-
inflammatory secretome (Ouchi et al., 2011). These secreted
factors, upregulated in obesity, reach the vascular wall through
the circulation where they can exert deleterious effects (Goldstein
and Scalia, 2007). As a consequence, induction of vascular
inflammation, endothelial dysfunction and smooth muscle cell
proliferation takes place. These processes are hallmarks of
vascular diseases and have been linked to PAR2 (Hirano and
Kanaide, 2003;Wronkowitz et al., 2014; Romacho et al., 2016). To
our knowledge, there are scarce reports about a direct connection
between obesity and PAR2 in the vasculature. In the present
study we aimed to explore the effect of CM as a model of
circulating adipokines under obesogenic conditions. We show
that obesity caused PAR2 upregulation in murine aortas, and
that CM of obese subjects triggered PAR2 induction in HCSMC.
Furthermore, CM induced HCSMC proliferation, COX2 and
pNF-κB in a PAR2-dependent manner. We demonstrated that
PAR2 activation and subsequent effects involved a transactivation
of the VEGFR2.
It has been reported that obesity upregulates PAR2 locally
in human AT as well as in AT of rats fed a HFD (Lim et al.,
2013). Adipokines released from AT are now acknowledged
as mediators of inter-organ crosstalk between the AT and the
vascular wall (Romacho et al., 2014). Indeed, pro-inflammatory
adipokines, which are upregulated in obesity, such as IL-
1α, IL-1β, and TNF-α have been described as potent PAR2
inducers in the vasculature (Nystedt et al., 1996; Hamilton et al.,
2001; Ritchie et al., 2007). Moreover, in human aorta PAR2
expression is enhanced in atherosclerotic lesions (Napoli et al.,
2004). Therefore, we aimed to explore if a low-grade chronic
inflammatory condition such as obesity had an impact on PAR2
expression not only in AT itself (Lim et al., 2013), but also
in the vascular wall. Interestingly, 24 weeks of HFD increased
PAR2 mRNA expression in murine aortas. PAR2 expression
in aortas was positively correlated with the body weight of
mice. Furthermore, solely CM from animals undergoing HFD
was able to induce PAR2 in HCSMC. These findings were
further corroborated in human vascular cells, namely HCAEC
and HCSMC, where human adipocyte-derived CM promoted
PAR2 upregulation on mRNA and protein levels. PAR2 mRNA
expression was positively correlated to the BMI of AT donors.
Altogether these data suggest that an obesogenic environment
provokes changes in the AT secretome leading to PAR2
upregulation in the vascular wall.
Vascular remodeling, characterized by proliferation and
migration of smooth muscle cells as well as apoptosis of
endothelial cells (Langille, 1993), is an early event in the
development of atherosclerosis (Lerman et al., 1998). We
recently demonstrated that adipocyte-derived CM can initiate
HCSMC proliferation (Schlich et al., 2013). In addition we
proved the participation of PAR2 in adipokine-induced HCSMC
proliferation (Wronkowitz et al., 2014). Our data suggest that
CM-mediated HCSMC proliferation as well as CM-mediated
HCAEC apoptosis is PAR2 dependent since it is abolished by
the PAR2 specific antagonist GB83 (Adams et al., 2012). The
specificity of this antagonist has been previously demonstrated
elsewhere (Barry et al., 2010). Accordingly, PAR2-AP induced
HCSMC proliferation thereby confirming the involvement of
PAR2. This result is in agreement with previous studies where
PAR2 agonist induced proliferation of smooth muscle (Bono
et al., 1997). Considering that PAR2 activation has been shown
to result in migration of smooth muscle cells (Pena et al.,
2012), these findings point toward a considerable role of PAR2
in vascular alterations. Further observations showed a trend
for correlation between CM-induced HCSMC proliferation and
PAR2 expression in these cells. Therefore, we assume that PAR2
abundance, upregulated by several CM-derived factors such as
TNFα and IL-1β (Nystedt et al., 1996; Ritchie et al., 2007),
might facilitate proliferation. However, the precise relevance
of PAR2 induction in the context of vascular and metabolic
diseases remains poorly understood and has to be further
elucidated.
There is evidence for a pivotal role of PAR2 during
atherosclerosis (Dery et al., 1998; Wronkowitz et al., 2014). It
is known that PAR2 agonism can lead to NFκB activation in
human coronary smooth muscle cells (Bretschneider et al., 1999;
Wronkowitz et al., 2014). To further elucidate the role of PAR2
in this process, we explored the impact of PAR2 agonism both
NFκB, as a master regulator of inflammatory gene expression
(Macfarlane et al., 2001) and COX2, another key regulator
of vascular inflammatory processes (Bagi et al., 2006). We
found that CM activated NF-κB and induced COX2 via PAR2.
Analogously, PAR2-AP significantly enhanced COX2 expression
and phosphorylation of NF-κB in HCSMC. Consistently, the
PAR2 antagonist GB83 prevented these deleterious effects
highlighting the importance of this receptor during atherogenesis
and inflammation-related diseases. Our results are in line
with other studies which showed PAR2-AP-stimulated COX2
expression in HUVECs (Syeda et al., 2006) and activation of
NF-κB in smooth muscle cells (Bretschneider et al., 1999). We
therefore assume a critical role of PAR2 in controlling COX2- and
NF-κB -mediated inflammation. However, one limitation of our
study is that we have not dissected the precise interaction between
COX2 and NF-κB.
Since it is known that the COX2 promoter region contains
putative NFκB binding sites in smoothmuscle cells (Tazawa et al.,
1994; Nie et al., 2003) we can speculate that PAR2 activation
most likely leads to NFκB translocation to the nucleus resulting
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FIGURE 5 | PAR2 mediated proliferation and COX2 upregulation requires intracellular VEGFR2 transactivation. (A) PAR2-AP-induced proliferation. HCSMC
were pre-treated with dobesilate (100 µM) or VEGFR2-NA (50 ng/ml) for 1 h, n = 4. (B) Effects of dobesilate and VEGFR2-NA on COX2 protein expression after 2 h;
n = 3. (C) Time course of the PAR2-AP-mediated phosphorylation of the VEGFR2 (Tyr1059); n = 4. (D) PAR2-AP-triggered VEGF release from HCSMC after 24 h,
n = 7. Data are mean values ± SEM (*p < 0.05 vs. time 0). Fetal calf serum (FCS), PAR2-activating peptide (PAR2-AP), VEGFR2 neutralizing antibody (VEGFR2-NA).
in COX2 expression. Nontheless, COX2 products such as PGE2
are able to increase the transcription of NFκB, thus positively
enhancing the inflammatory signaling (Poligone and Baldwin,
2001). So far there are no data available if and how exactly PAR2-
mediated signaling pathways involve both NFκB and COX2. In
the light of our data we cannot specifically dissect whether NFκB
leads to COX2 induction, or if COX2 induction leads to NF-κB
activity.
In this study we have focused on the effects of CM
on inflammation and proliferation as two key processes in
atherogenesis, since the role of PAR2 in adipokine-induced
impairment of vascular reactivity (Romacho et al., 2016) and
the effect of CM on endothelial migration has already been
proven (Hu et al., 2013). CM contains numerous molecules
derived from adipocytes, which serve as potential ligands for
PAR2, thereby contributing to promote PAR2-mediated effects,
such as proliferation. We have previously demonstrated that
the adipokine DPP4 is an activator of PAR2 existing in the
CM and driving proliferation through ERK1/2 activation in a
PAR2-dependent manner (Wronkowitz et al., 2014). However,
our group showed that CM-mediated HCSMC proliferation is
mainly due to VEGF abundance (Schlich et al., 2013), which
is even higher during obesity (Silha et al., 2005; Loebig et al.,
2010; Disanzo and You, 2014). Among the potential factors
present in the CM promoting PAR2-mediated proliferation
and inflammation we now identified VEGF as an adipokine
upregulated in murine CM from AT explants upon HFD
(Supplementary Figure 2A). Moreover, VEGF abundance is
positively correlated to BMI of human adipocyte donors
(Supplementary Figure 2B). VEGF signaling occurs via receptor
tyrosine kinases (RTKs) particularly VEGF receptor 1 and 2
(VEGFR1 and VEGFR2), of whom the latter is known to be
responsible for most of the VEGF-induced actions, including
proliferation (Waltenberger et al., 1994; Ferrara et al., 2003;
Shibuya and Claesson-Welsh, 2006). In the present study,
we prove that PAR2 is involved in HCSMC proliferation.
Therefore, we hypothesize that PAR2 and VEGFR2 interaction
may lead to COX2 induction resulting in HCSMC proliferation.
Nevertheless, there are several factors in the CM, which have
to be identified in future studies, potentially leading to PAR2
activation, induction or both via distinct mechanisms such as
binding to the binding pocket at the extracellular loop 2 (sDPP4)
(Wronkowitz et al., 2014), the cleavage of the N-terminus and
unmasking of the tethered ligand (trypsin, cathepsin S) or
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the disarming of the receptor (cathepsin G) (Kagota et al.,
2016). Synthetic PAR2-AP activate PAR2 due to binding to
the binding pocket located at the extracellular loop 2 (Adams
et al., 2011) which might result in divergent effects compared
with CM-mediated actions. Furthermore, we cannot discard the
participation of other novel mediators of atherogenesis such as
miRNAS (Blumensatt et al., 2014; Novak et al., 2015).
Receptor crosstalk between PARs, other GPCRs and RTKs
such as the VEGF receptor has been observed in various
cell types for example endothelial or smooth muscle cells
(Gschwind et al., 2001; Chandrasekharan et al., 2010; Gieseler
et al., 2013; Mazor et al., 2013). To determine if receptor
interaction is required in PAR2-mediated proliferation and
COX2 upregulation, we assessed the effect of the VEGFR2
inhibitor dobesilate (Angulo et al., 2011) and a VEGFR2-NA.
Specific activation of PAR2 by addition of PAR2-AP induced
proliferation and COX2 expression which were suppressed by
both dobesilate and the VEGFR2-NA. Furthermore, activation of
PAR2 resulted in phosphorylation of VEGFR2. Altogether, these
results point toward a PAR2-induced transactivation of VEGFR2.
Since both receptors are present on the surface of the same
cell types, receptor interaction is plausible. Receptor crosstalk
occurs via different components such as the release of agonists or
transactivation due to intracellular signal transducers (Gieseler
et al., 2013). To shed more light onto underlying mechanisms
we analyzed whether transactivation of VEGFR2 was ligand
dependent or not. The PAR2 agonist did not increase VEGF
release from HCSMC indicating that VEGFR2 transactivation
is VEGF independent. However, VEGF production in response
to PAR2 activation has been described in other cell types (Liu
and Mueller, 2006; Dutra-Oliveira et al., 2012; Rasmussen et al.,
2012). Nonetheless, other intracellular molecules such as tyrosine
kinase Src, ROS and protein tyrosine phosphatases have been
discussed to be potential mediators of RTK and PAR interaction
(Gieseler et al., 2013). In our case, preliminary data discard
the participation of Src (data not shown). Data on receptor
transactivation are based mainly on findings focusing on PAR1
and RTKs, others than VEGFR2, thereby demonstrating the
novelty of our results. Since precise mechanisms whereby PAR2
promotes activation of VEGFR2 and subsequent proliferation
as well as COX2 induction are not yet fully understood, only
further investigations will shed light on the specific mechanisms
mediating this novel PAR2-VEGFR2 transactivation.
CONCLUSION
We have demonstrated a pivotal role of PAR2 in obesity-related
pro-atherogenic events. Adipocyte-derived CM from obese
subjects triggered PAR2 induction in HCAEC and HCSMC.
In turn, PAR2 upregulation might facilitate CM-induced
proliferation and COX2 induction in HCSMC. We propose that
during obesity upregulation and activation of PAR2 by elevated
levels of pro-inflammatory adipokines in the circulation, results
in NFκB activation, COX-2 induction and proliferation, key
processes in the development of atherosclerosis (GRAPHICAL
ABSTRACT). Importantly, these pro-atherogenic events
involved transactivation of the VEGFR2 by PAR2. Therefore,
we propose an essential function of PAR2 in vascular cells and
present PAR2 as a potentially useful therapeutic target in the
treatment of obesity-associated atherogenesis. Therefore, it is of
great importance to investigate the exact mechanisms by which
PAR2 transactivates the VEGFR2 and to identify certain PAR2
activators triggering the observed effects.
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